ELVN Quote, Financials, Valuation and Earnings

Coherus Oncology, Inc. has a net margin of -- compared to Enliven Therapeutics, Inc.'s net margin of -363.56%. Enliven Therapeutics, Inc.'s return on equity of -25.64% beat Coherus Oncology, Inc.'s return on equity of --.

Enliven Therapeutics, Inc. has a consensus price target of $47.43, signalling upside risk potential of 7.57%. On the other hand Coherus Oncology, Inc. has an analysts' consensus of $6.75 which suggests that it could grow by 304.19%. Given that Coherus Oncology, Inc. has higher upside potential than Enliven Therapeutics, Inc., analysts believe Coherus Oncology, Inc. is more attractive than Enliven Therapeutics, Inc..

Enliven Therapeutics, Inc. has a beta of 0.261, which suggesting that the stock is 73.945% less volatile than S&P 500. In comparison Coherus Oncology, Inc. has a beta of 1.033, suggesting its more volatile than the S&P 500 by 3.258%.

Enliven Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Coherus Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enliven Therapeutics, Inc. pays -- of its earnings as a dividend. Coherus Oncology, Inc. pays out -- of its earnings as a dividend.

Enliven Therapeutics, Inc. quarterly revenues are --, which are smaller than Coherus Oncology, Inc. quarterly revenues of $12.7M. Enliven Therapeutics, Inc.'s net income of -$29.7M is higher than Coherus Oncology, Inc.'s net income of -$46.3M. Notably, Enliven Therapeutics, Inc.'s price-to-earnings ratio is -- while Coherus Oncology, Inc.'s PE ratio is 1.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enliven Therapeutics, Inc. is -- versus 4.65x for Coherus Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kodiak Sciences, Inc. has a net margin of -- compared to Enliven Therapeutics, Inc.'s net margin of --. Enliven Therapeutics, Inc.'s return on equity of -25.64% beat Kodiak Sciences, Inc.'s return on equity of -201.8%.

Enliven Therapeutics, Inc. has a consensus price target of $47.43, signalling upside risk potential of 7.57%. On the other hand Kodiak Sciences, Inc. has an analysts' consensus of $56.33 which suggests that it could grow by 34.8%. Given that Kodiak Sciences, Inc. has higher upside potential than Enliven Therapeutics, Inc., analysts believe Kodiak Sciences, Inc. is more attractive than Enliven Therapeutics, Inc..

Enliven Therapeutics, Inc. has a beta of 0.261, which suggesting that the stock is 73.945% less volatile than S&P 500. In comparison Kodiak Sciences, Inc. has a beta of 2.394, suggesting its more volatile than the S&P 500 by 139.374%.

Enliven Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kodiak Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enliven Therapeutics, Inc. pays -- of its earnings as a dividend. Kodiak Sciences, Inc. pays out -- of its earnings as a dividend.

Enliven Therapeutics, Inc. quarterly revenues are --, which are smaller than Kodiak Sciences, Inc. quarterly revenues of --. Enliven Therapeutics, Inc.'s net income of -$29.7M is higher than Kodiak Sciences, Inc.'s net income of -$61.5M. Notably, Enliven Therapeutics, Inc.'s price-to-earnings ratio is -- while Kodiak Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enliven Therapeutics, Inc. is -- versus -- for Kodiak Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals, Inc. has a net margin of -- compared to Enliven Therapeutics, Inc.'s net margin of -18.24%. Enliven Therapeutics, Inc.'s return on equity of -25.64% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -42.53%.

Enliven Therapeutics, Inc. has a consensus price target of $47.43, signalling upside risk potential of 7.57%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $668.57 which suggests that it could grow by 30.61%. Given that Madrigal Pharmaceuticals, Inc. has higher upside potential than Enliven Therapeutics, Inc., analysts believe Madrigal Pharmaceuticals, Inc. is more attractive than Enliven Therapeutics, Inc..

Enliven Therapeutics, Inc. has a beta of 0.261, which suggesting that the stock is 73.945% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -0.995, suggesting its less volatile than the S&P 500 by 199.535%.

Enliven Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enliven Therapeutics, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Enliven Therapeutics, Inc. quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $321.1M. Enliven Therapeutics, Inc.'s net income of -$29.7M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$58.6M. Notably, Enliven Therapeutics, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enliven Therapeutics, Inc. is -- versus 11.47x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of -- compared to Enliven Therapeutics, Inc.'s net margin of -93.07%. Enliven Therapeutics, Inc.'s return on equity of -25.64% beat Sarepta Therapeutics, Inc.'s return on equity of -64.94%.

Enliven Therapeutics, Inc. has a consensus price target of $47.43, signalling upside risk potential of 7.57%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $21.70 which suggests that it could fall by -6.19%. Given that Enliven Therapeutics, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Enliven Therapeutics, Inc. is more attractive than Sarepta Therapeutics, Inc..

Enliven Therapeutics, Inc. has a beta of 0.261, which suggesting that the stock is 73.945% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.289, suggesting its less volatile than the S&P 500 by 71.103%.

Enliven Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enliven Therapeutics, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

Enliven Therapeutics, Inc. quarterly revenues are --, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $442.9M. Enliven Therapeutics, Inc.'s net income of -$29.7M is higher than Sarepta Therapeutics, Inc.'s net income of -$412.2M. Notably, Enliven Therapeutics, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enliven Therapeutics, Inc. is -- versus 1.09x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.